Ceeto Capital Group’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Ceeto Capital Group’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-44,000	Closed	-$330K	–	158
2021 Q4	$330K	Sell	44,000 -15,000	-25%	-$130K	0.14%	125
2021 Q3	$532K	Sell	59,000 -8,000	-12%	-$79.1K	0.25%	91
2021 Q2	$802K	Sell	67,000 -7,000	-9%	-$79.3K	0.36%	74
2021 Q1	$927K	Sell	74,000 -6,000	-8%	-$80.8K	0.45%	64
2020 Q4	$1.25M	Sell	80,000 -3,500	-4%	-$41K	0.63%	45
2020 Q3	$789K	Hold	83,500	–	–	0.44%	64
2020 Q2	$748K	Buy	83,500 +33,500	+67%	+$311K	0.48%	60
2020 Q1	$319K	Buy	50,000 +12,000	+32%	+$89K	0.26%	94
2019 Q4	$318K	Hold	38,000	–	–	0.21%	105
2019 Q3	$344K	Hold	38,000	–	–	0.25%	102
2019 Q2	$409K	Sell	38,000 -3,000	-7%	-$31.9K	0.3%	92
2019 Q1	$391K	Sell	41,000 -12,000	-23%	-$123K	0.29%	94
2018 Q4	$608K	Hold	53,000	–	–	0.5%	61
2018 Q3	$898K	Buy	53,000 +1,000	+2%	+$15.2K	0.62%	55
2018 Q2	$738K	Buy	52,000 +6,000	+13%	+$99.7K	0.55%	61
2018 Q1	$874K	Buy	+46,000	New	+$983K	0.66%	49

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Ceeto Capital Group's SGMO Position: Q1 2022 in Review

Ceeto Capital Group sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2022, closing a stake of 44,000 shares — an estimated $330K sold.

Ceeto Capital Group first reported a position in SGMO in Q1 2018 and held it in 16 quarters. The position peaked at $1.25M in Q4 2020. 195 funds tracked by Wall St. Rank hold SGMO as of Q1 2022.

Ceeto Capital Group reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2022 after selling out during the quarter.
Ceeto Capital Group sold 44,000 SANGAMO THERAPEUTICS INC shares in Q1 2022, an estimated $330K.
Ceeto Capital Group first reported a position in SANGAMO THERAPEUTICS INC in Q1 2018 and held it in 16 quarters.
Ceeto Capital Group's SANGAMO THERAPEUTICS INC position peaked at $1.25M in Q4 2020.
195 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2022.

Based on Ceeto Capital Group's 13F filing for Q1 2022, filed 16 May 2022.